Fig. 4

miR-27b inhibition halts tumor growth and angiogenesis. Mice were implanted with subcutaneous LLC tumors in the right flank and tumor growth was measured daily. When tumors reached 5–6 mm in diameter, the animals were treated every 2 days with intraperitoneal injections of NC RNAi, miR-27b mimic 27b(M) or inhibitor, 27b(I) at 100 μg per mouse per injection (n = 5). After 1 week, the mice were sacrificed, tumors harvested, weighted and cryopreserved for further analyses. (a) Gross appearance of the tumors. (b, c) Tumor volume (b) and weight (c) at the endpoint. Data is presented as dot plot with whiskers and median values are shown. P values are calculated using Kruskal-Wallis method. (d, e) Five-μm cryosections were stained for the endothelial marker, CD31 (D), and MVD measured as total CD31-positive area (e). The results are presented as box plot with whiskers and P value calculated using Wilcoxon Signed Rank method. Note decreased MVD when miR-27b is inhibited, 27b(I). NT, no treatment; NC, negative control; 27b(M), miR-27b mimic; 27b(I), miR-27b inhibitor